Skip to content
DataLookout
Menu

NCT02897063

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 13 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: enrollment goal was not met. Show 4 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Study completion date changed from estimate of Dec 2026 to Oct 2026
    • Study description revised
    • Site details revised
  2. Notable Primary completion date: Sep 2025 to Sep 2026
    • Study completion date: Dec 2025 to Dec 2026
    • Site contact updated
    v15
  3. Notable Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Dec 2024 to Dec 2025
    • Site contact updated
    v14
  4. Minor Primary completion date: Mar 2024 to Sep 2024
    • Study completion date: Aug 2024 to Dec 2024
    v13
  5. Notable Primary completion date: Mar 2023 to Mar 2024
    • Study completion date: Aug 2023 to Aug 2024
    v12
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Site contact updatedv11
  2. Notable Primary completion date: Mar 2021 to Mar 2023
    • Study completion date: Aug 2021 to Aug 2023
    v10
  3. Notable Trial status: Suspended to Recruiting
    • Site details revised
    v9
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Recruitment is temporarily suspended due to COVID-19 outbreak
    • Site details revised
    v8
  5. Minor Site contact updatedv6
  6. Notable Phase: Not applicable to Phase 1
    • Lead sponsor: Vanderbilt University to Vanderbilt University Medical Center
    v4
  7. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 2 words
    • Start date: Aug 2016 to Sep 2016
    • Site details revised
    • Study description expanded, about 1 word
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Stroke volume
Timeframe: Up to 10 min of head up tilt

Arms and interventions

Droxidopa and PlaceboExperimental

Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.

Midodrine and PlaceboExperimental

Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.

Drugs: Droxidopa, Midodrine, Placebo

Sites

1 site in 1 country

  • Autonomic Dysfunction Center/ Vanderbilt University Medical CenterNashville, Tennessee, United States